• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

磷酸二酯酶抑制剂:全身和冠状动脉血流动力学的改变

Phosphodiesterase inhibitors: alterations in systemic and coronary hemodynamics.

作者信息

Chatterjee K

机构信息

University of California, San Francisco.

出版信息

Basic Res Cardiol. 1989;84 Suppl 1:213-24. doi: 10.1007/BF02650361.

DOI:10.1007/BF02650361
PMID:2684145
Abstract

This paper reviews the effect on myocardial contractility, left ventricular afterload and left ventricular distensibility induced by the following phosphodiesterase inhibitors: Enoximone, piroximone, RO 13-6438, amrinone and milrinone. For all these compounds, direct positive inotropic effects have been shown in experimental studies. For amrinone and milrinone, a direct stimulating effect on myocardial contractility has been demonstrated by an increase in dP/dtmax when intracoronary applications of the compounds were performed. A direct stimulating effect on the myocardium was also demonstrated for enoximone and piroximone by analyzing the systolic pressure versus end-systolic volume ratio. For all of the phosphodiesterase inhibitors, a marked decrease of systemic vascular resistance has been observed indicating direct peripheral vasodilation. Although it has been demonstrated that phosphodiesterase inhibition increases left ventricular distensibility, the nature of this effect is not clear. For most of the phosphodiesterase inhibitors an increase in myocardial oxygen requirements was demonstrated due to overall contractility increase. However, these phosphodiesterase inhibitors induce increased coronary blood flow in excess so that a direct effect of these compounds on the coronary vasculature has been postulated. The clinical significance of such changes, however, remains unclear.

摘要

本文综述了以下磷酸二酯酶抑制剂对心肌收缩力、左心室后负荷和左心室舒张性的影响:依诺昔酮、吡罗昔酮、RO 13-6438、氨力农和米力农。对于所有这些化合物,实验研究均已表明其具有直接的正性肌力作用。对于氨力农和米力农,当进行冠状动脉内给药时,通过dP/dtmax的增加证明了它们对心肌收缩力具有直接刺激作用。通过分析收缩压与收缩末期容积比,也证明了依诺昔酮和吡罗昔酮对心肌具有直接刺激作用。对于所有磷酸二酯酶抑制剂,均观察到全身血管阻力显著降低,表明其具有直接的外周血管舒张作用。虽然已证明磷酸二酯酶抑制可增加左心室舒张性,但其作用性质尚不清楚。对于大多数磷酸二酯酶抑制剂,由于整体收缩力增加,心肌氧需求增加。然而,这些磷酸二酯酶抑制剂可使冠状动脉血流量过度增加,因此推测这些化合物对冠状动脉血管系统具有直接作用。然而,这种变化的临床意义仍不清楚。

相似文献

1
Phosphodiesterase inhibitors: alterations in systemic and coronary hemodynamics.磷酸二酯酶抑制剂:全身和冠状动脉血流动力学的改变
Basic Res Cardiol. 1989;84 Suppl 1:213-24. doi: 10.1007/BF02650361.
2
[Dose-dependent effect of amrinone on hemodynamics, myocardial circulation and myocardial energy requirement. An experimental study].[氨力农对血流动力学、心肌循环及心肌能量需求的剂量依赖性效应。一项实验研究]
Z Kardiol. 1985 Feb;74(2):76-84.
3
Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow.磷酸二酯酶抑制对心肌耗氧量和冠状动脉血流量的影响。
Am J Cardiol. 1989 Jan 3;63(2):23A-26A. doi: 10.1016/0002-9149(89)90388-3.
4
A comparison of three phosphodiesterase type III inhibitors on mechanical and metabolic function in guinea pig isolated hearts.
Anesth Analg. 2006 Jun;102(6):1646-52. doi: 10.1213/01.ane.0000216290.74626.27.
5
Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs.左西孟旦对清醒犬的全身和冠状动脉血流动力学作用及左心室功能的影响
J Cardiovasc Pharmacol. 1995 Aug;26(2):179-88. doi: 10.1097/00005344-199508000-00002.
6
Effects of enoximone and R 80122, a new selective phosphodiesterase III inhibitor, on hemodynamics and myocardial energetics in patients with ischemic heart disease.
Anesth Analg. 1994 Dec;79(6):1059-65. doi: 10.1213/00000539-199412000-00007.
7
Hemodynamic response and effects on myocardial energetics of 3-cyano-2-morpholino-5-(pyrid-4-yl)pyridine (AWD 122-14) in anesthetized minipigs.
Pharmazie. 1993 Sep;48(9):690-4.
8
Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs.R 80122、依诺昔酮和米力农对犬左心室磷酸二酯酶同工酶的体外比较作用以及对正常和顿抑心肌收缩力的体内比较作用。
J Cardiovasc Pharmacol. 1992 May;19(5):714-22.
9
Effect of combining phosphodiesterase III inhibitors with St Thomas Hospital's solution used as transplantation preservative solution in isolated rat hearts.磷酸二酯酶III抑制剂与用作离体大鼠心脏移植保存液的圣托马斯医院溶液联合使用的效果。
Transplant Proc. 2006 Jun;38(5):1253-8. doi: 10.1016/j.transproceed.2006.02.062.
10
Myocardial energetics in patients with dilated cardiomyopathy. Influence of nitroprusside and enoximone.扩张型心肌病患者的心肌能量代谢。硝普钠和依诺昔酮的影响。
Circulation. 1989 Jul;80(1):51-64. doi: 10.1161/01.cir.80.1.51.

引用本文的文献

1
Oral Enoximone as an Alternative to Protracted Intravenous Medication in Severe Pediatric Myocardial Failure.口服依诺昔酮作为小儿重症心肌衰竭中长时间静脉用药的替代方案
Pediatr Cardiol. 2016 Oct;37(7):1297-301. doi: 10.1007/s00246-016-1433-4. Epub 2016 Jul 5.
2
Milrinone and low cardiac output following cardiac surgery in infants: is there a direct myocardial effect?米力农与婴儿心脏手术后的心输出量降低:是否存在直接心肌效应?
Pediatr Cardiol. 2005 Sep-Oct;26(5):642-5. doi: 10.1007/s00246-005-0881-z.
3
Cardiac contractility modulation with the impulse dynamics signal: studies in dogs with chronic heart failure.

本文引用的文献

1
Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease.氨力农对冠心病所致严重充血性心力衰竭患者心肌能量代谢及血流动力学的影响。
Circulation. 1980 Jul;62(1):28-34. doi: 10.1161/01.cir.62.1.28.
2
Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone.米力农治疗的充血性心力衰竭患者舒张功能指标的改善。
Circulation. 1984 Dec;70(6):1030-7. doi: 10.1161/01.cir.70.6.1030.
3
Mechanisms of improved left ventricular function following intravenous MDL 17,043 in patients with severe chronic heart failure.
基于冲动动力学信号的心脏收缩力调制:对慢性心力衰竭犬的研究
Heart Fail Rev. 2001 Jan;6(1):45-53. doi: 10.1023/a:1009855208097.
4
Characterization of the inotropic and arrhythmogenic action of the sodium channel activator BDF 9148: a comparison to its S-enantiomer BDF 9196, to its congener DPI 201-106, to norepinephrine, and to ouabain.钠通道激活剂BDF 9148的变力作用和致心律失常作用的表征:与其S-对映体BDF 9196、同系物DPI 201-106、去甲肾上腺素及哇巴因的比较
Basic Res Cardiol. 1994 Jan-Feb;89(1):61-79. doi: 10.1007/BF00788678.
重度慢性心力衰竭患者静脉注射MDL 17,043后左心室功能改善的机制
Am Heart J. 1984 Nov;108(5):1278-84. doi: 10.1016/0002-8703(84)90754-3.
4
Intravenous and oral MDL 17043 (a new inotrope-vasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients.
J Am Coll Cardiol. 1984 Nov;4(5):884-9. doi: 10.1016/s0735-1097(84)80047-9.
5
Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species.新型强效心脏双吡啶类药物米力农对多种动物离体组织强心作用的特性研究
J Cardiovasc Pharmacol. 1983 Sep-Oct;5(5):804-11. doi: 10.1097/00005344-198309000-00015.
6
Characterization of the cardiovascular activities of a new cardiotonic agent, MDL 17043 (1,3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazole-2-one).
J Cardiovasc Pharmacol. 1982 Sep-Oct;4(5):721-9. doi: 10.1097/00005344-198209000-00005.
7
Epinephrine infusion in man. Standardization, normal response, and abnormal response in idiopathic hypertrophic subaortic stenosis.人体肾上腺素输注。特发性肥厚性主动脉瓣下狭窄的标准化、正常反应及异常反应
Circulation. 1971 Jan;43(1):137-44. doi: 10.1161/01.cir.43.1.137.
8
Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio.犬左心室瞬时压力-容积比的负荷独立性以及肾上腺素和心率对该比值的影响。
Circ Res. 1973 Mar;32(3):314-22. doi: 10.1161/01.res.32.3.314.
9
Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation.米力农治疗充血性心力衰竭:急性和慢性血流动力学及临床评估
J Am Coll Cardiol. 1985 Aug;6(2):453-9. doi: 10.1016/s0735-1097(85)80185-6.
10
RO13-6438, a new inotrope-vasodilator: systemic and coronary hemodynamic effects in congestive heart failure.RO13 - 6438,一种新型强心血管扩张剂:对充血性心力衰竭患者的全身和冠状动脉血流动力学影响
Am J Cardiol. 1985 Jun 1;55(13 Pt 1):1539-44. doi: 10.1016/0002-9149(85)90969-5.